| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1542e8802a0e6a7a8a7c6bd5627eb857 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate |
2005-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9aeaaa3f82c8f533c5fbef4addc4650c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_460d0e62ed0278ff3ab6d67962333c08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a861ef15b8014ccad2279a882a723f97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b28fce01ca327127b56ab175e7a92bf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bd89739cdda496a23d16600f8f0974f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74faee13278a1c972332ffd2326c02fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2aa2bf44fd046ec4a4cb5c97e2084f01 |
| publicationDate |
2006-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2580135-A1 |
| titleOfInvention |
7-azaindoles and their use as ppar agonists |
| abstract |
The invention relates to 7-azaindoles and to their physiologically acceptable salts and physiologically functional derivatives showing PPAR agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance in involved. |
| priorityDate |
2004-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |